Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie ( (ABBV) ) has issued an update.
On February 14, 2025, AbbVie announced the appointment of CEO Robert A. Michael as chairman of the board, effective July 1, 2025, succeeding Richard A. Gonzalez, who will retire from the board. This leadership change marks a new phase for AbbVie, with expectations for continued growth and innovation under Michael’s guidance, leveraging his extensive experience and successful track record within the company.
More about AbbVie
AbbVie is a biopharmaceutical company focused on discovering and delivering innovative medicines and solutions across therapeutic areas such as immunology, oncology, neuroscience, and eye care, as well as in its Allergan Aesthetics portfolio.
YTD Price Performance: 9.89%
Average Trading Volume: 6,190,376
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $341.9B
For an in-depth examination of ABBV stock, go to TipRanks’ Stock Analysis page.